Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave CEO Resigns, Says Firm s New Business Model Represents Excellent Time for New Leadership

NEW YORK, Dec. 15 (GenomeWeb News) - Third Wave Technologies today said that President and CEO John Puisis has resigned.


Kevin Conroy, vice president and general counsel, will replace Puisis. Conroy will also join Third Wave's board.


In a statement, Puisis said he came to Third Wave "and stayed for a specific purpose. With a new business model and ... management team in place, that purpose has been completed.


"Given that we fundamentally have a new company, I believe this is an excellent time to make the switch," Puisis added.


Puisis is credited with helping to engineer Third Wave's evolution from a tool vendor into a molecular diagnostics player.

Conroy, 40 years old, came to Third Wave from GE Healthcare, where he helped integrate the firm's acquisition of Instrumentarium Corp. A former lawyer, he also helped develop, manage, and grow the intellectual property portfolio of GE's its $1.3-billion patient-monitoring, medical imaging, and health care software business.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.